Dr. Garon on Differences Between Antiangiogenic Agents in Lung Cancer
In Partnership With:
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.
Unlike bevacizumab (Avastin), ramucirumab (Cyramza) and nintedanib (Ofev) target the VEGF receptor. Ramucirumab is a monoclonal antibody and nintedanib is a tyrosine kinase inhibitor.
There have been multiple attempts to add a TKI to chemotherapy in order to achieve the same benefits seen with bevacizumab plus chemotherapy, says Garon.
